Intermountain Forms Value-Based Care Company
A new comprehensive health platform company will focus on elevating value-based care capabilities with providers, payers, healthcare systems, and ACOs.
Rajesh Shrestha,
Intermountain Healthcare is forming a new value-based care company.
Called Castell, the company will offer a comprehensive platform of tools and services to support practice transformation and improvement. These resources will help all parts of the health ecosystem promote wellness for patients and excel within a value-based healthcare world.
“Intermountain has actively developed tools and initiatives to help providers and others successfully implement value-based care for years,” says Rajesh Shrestha, president and CEO of Castell. “Castell is one part of that work that we’re excited to officially share now."
Related article: Intermountain Healthcare, deCODE Launch Largest DNA Mapping Project in United States
The new company will offer a comprehensive platform of tools and services to support transformation and improvement:
- A proven value-based clinical care model called “Reimagined Primary Care”
- A technology and analytics platform to guide care
- Streamlined affiliated network management
- Digital tools to address virtual care, patient experience, and social determinants of health
- Access to cutting-edge initiatives and innovation coming out of Intermountain Healthcare
- Opportunity to utilize care pathways and clinical best practices developed by Intermountain Healthcare
“We continually see that without the right level of support, it is difficult for providers, health systems, payers, and others to thrive in a value-based healthcare world,” Shrestha says. “Intermountain’s day-to-day frontline experience and success in value-based care management programs make us uniquely prepared to extend our services to others through Castell. We are energized by this opportunity to simplify value-based care and help set the direction for the healthcare of the future.”
Prime Therapeutics Finds No Medical Cost Offsets for GLP-1 Obesity Drugs | AMCP Annual 2025
April 1st 2025A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control group.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Unrealistic Portrayals of Cardiac Arrest in Contemporary Film | ACC 2025
March 31st 2025Cardiac arrests in contemporary film are largely inaccurate when it comes to survival rate and etiology, according to a poster presented today at the American College of Cardiology conference held March 29 to 31 in Chicago.
Read More
